Epstein-Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing.
Epstein-Barr virus (EBV) has been implicated in the pathogenesis of primary central nervous system lymphomas (PCNLs) in immunocompetent hosts. To investigate the role of EBV in the pathogenesis of PCNLs in immunocompetent hosts, this study assessed six PCNL cases (elderly male immunocompetent patients; age ≥60 years) histologically and immunohistochemically, and an EBV genetic study was performed. Histologically, all cases were diagnosed as diffuse large B-cell lymphoma with extensive necrosis. In all six cases, PCNL cells showed immunohistochemical positivity for latent membrane protein 1 (LMP-1) and Epstein-Barr nuclear 2 (EBNA2). Lymphoma cells also showed positive signals for EBV-encoded small RNAs (EBERs) on in-situ hybridization. EBV subtyping-PCR analysis demonstrated that one case was EBNA 2B type and the other five cases were EBNA 2A type, and two cases were EBV wild-type and four cases showed 30-bp LMP-1 deletion by PCR analysis. It is therefore possible that LMP gene deletion or EBNA-2 strain type are important in the tumorigenesis of EBV-positive PCNLs. In addition, EBV-positive PCNLs in immunocompetent hosts may be related to immunological deterioration derived from the aging process.
Sugita
Yasuo
Y
Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan. sugita_yasuo@med.kurume-u.ac.jp
Terasaki
Mizuhiko
M
Niino
Daisuke
D
Ohshima
Koichi
K
Fumiko
Arakawa
A
Shigemori
Minoru
M
Sato
Yasuharu
Y
Asano
Naoko
N
D000368:Aged; D000369:Aged, 80 and over; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000235:genetics* / Q000821:virology; D019309:Epstein-Barr Virus Nuclear Antigens / Q000235:genetics*; D017353:Gene Deletion; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000473:pathology / Q000821:virology*; D008297:Male; D016133:Polymerase Chain Reaction; D014763:Viral Matrix Proteins / Q000235:genetics*; D014764:Viral Proteins / Q000235:genetics*
C402641:EBNA-2 protein, Human herpesvirus 4; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D019309:Epstein-Barr Virus Nuclear Antigens; D014763:Viral Matrix Proteins; D014764:Viral Proteins
Lancet. 1991 Oct 19;338(8773):969-73
1681341
Pathol Int. 2006 Mar;56(3):112-6
16497243
Neuro Oncol. 2007 Jul;9(3):364-9
17522336
Am J Surg Pathol. 2003 Jan;27(1):16-26
12502924
J Clin Microbiol. 2001 Nov;39(11):4152-4
11682546
Hum Pathol. 1990 May;21(5):545-50
2159947
J Virol. 2004 Dec;78(23):12987-95
15542650
Leuk Lymphoma. 2000 Jul;38(3-4):373-80
10830744
Pathol Int. 2008 Nov;58(11):695-700
18844934
Mod Pathol. 1990 Sep;3(5):609-12
2172960
Clin Cancer Res. 2007 Apr 15;13(8):2504-11
17438111
Blood. 1993 Apr 15;81(8):2102-9
8386027
Virology. 1985 Nov;147(1):81-98
2998073
Cancer. 1991 Jan 15;67(2):444-8
1845947
Cancer Sci. 2008 Feb;99(2):296-302
18271928
Histopathology. 1999 Dec;35(6):539-50
10583578
Clin Cancer Res. 2007 Sep 1;13(17):5124-32
17785567
Clin Neuropathol. 1996 Mar-Apr;15(2):79-86
8925601
Int J Cancer. 2002 Apr 1;98(4):567-72
11920617
Oncogene. 1993 Jun;8(6):1575-83
8389032
Histopathology. 2001 Aug;39(2):163-71
11493333
Blood. 1996 Jul 1;88(1):242-51
8704180
Cancer Res. 2003 Mar 1;63(5):965-71
12615710
J Clin Pathol. 1992 Sep;45(9):770-5
1401205
Diagn Mol Pathol. 1993 Mar;2(1):42-9
8287225
J Clin Oncol. 2002 Dec 15;20(24):4643-8
12488408
J Neuropathol Exp Neurol. 2008 Nov;67(11):1103-11
18957891